Payer-Addressable Burden of Crohn’s Disease in Members Treated with Biologics in the United States: Actuarial Analysis Findings from RAINBOW

REFERENCES

• Dahlhamer, J. M., E. P. Zammitti, B. W. Ward, A. G. Wheaton, and J. B. Croft. 2016. Prevalence of inflammatory bowel disease among adults aged ≥ 18 years—United States, 2015. Morbidity and Mortality Weekly Report 65(42): 1166–69.
   Web of Science ®Google Scholar
• Feagan, B. G., C. M. Kozma, T. L. Slaton, W. H. Olson, and G. J. Wan. 2014. Healthcare costs for Crohn’s disease patients treated with infliximab: A propensity weighted comparison of the effects of treatment adherence. Journal of Medical Economics 17(12): 872–80. doi:10.3111/13696998.2014.950669
   PubMedGoogle Scholar
• Feuerstein, J. D., E. Y. Ho, E. Shmidt, H. Singh, Y. Falck-Ytter, S. Sultan, J. P. Terdiman, S. Sultan, B. L. Cohen, K. Chachu, et al. 2021. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology 160(7): 2496–508. doi:10.1053/j.gastro.2021.04.022
   PubMed Web of Science ®Google Scholar
• Ganz, M. L., R. Sugarman, R. Wang, B. B. Hansen, and J. Håkan-Bloch. 2016. The economic and health-related impact of Crohn's disease in the United States: Evidence from a nationally representative survey. Inflammatory Bowel Diseases 22(5): 1032–41. doi:10.1097/MIB.0000000000000742
   PubMed Web of Science ®Google Scholar
• Lichtenstein, G. R., E. V. Loftus, K. L. Isaacs, M. D. Regueiro, L. B. Gerson, and B. E. Sands. 2018. ACG clinical guideline: Management of Crohn's disease in adults. American Journal of Gastroenterology 113(4): 481–517. doi:10.1038/ajg.2018.27
   PubMed Web of Science ®Google Scholar
• Manceur, A. M., Z. Ding, E. Muser, C. Obando, J. Voelker, D. Pilon, F. Kinkead, M.-H. Lafeuille, and P. Lefebvre. 2020. Burden of Crohn’s disease in the United States: Long-term healthcare and work-loss related costs. Journal of Medical Economics 23(10): 1092–101. doi:10.1080/13696998.2020.1789649
   PubMed Web of Science ®Google Scholar
• Park, K. T., O. G. Ehrlich, J. I. Allen, P. Meadows, E. M. Szigethy, K. Henrichsen, S. C. Kim, R. C. Lawton, S. M. Murphy, M. Regueiro, et al. 2020. The cost of inflammatory bowel disease: An initiative from the Crohn’s & Colitis Foundation. Inflammatory Bowel Diseases 26(1): 1–10. doi:10.1093/ibd/izz104
   PubMed Web of Science ®Google Scholar
• Patel, H., D. Latremouille-Viau, R. Burne, S. Shi, and S. Adsul. 2019. Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease. Crohn's & Colitis 360 1(2): otz022. doi:10.1093/crocol/otz022
   Google Scholar
• Pillai, N., J. E. Lupatsch, M. Dusheiko, M. Schwenkglenks, M. Maillard, C. S. Sutherland, and V. E. H. Pittet. 2020. Evaluating the cost-effectiveness of early compared with late or no biologic treatment to manage Crohn's disease using real-world data. Journal of Crohn's and Colitis 14(4): 490–500. doi:10.1093/ecco-jcc/jjz169
   PubMed Web of Science ®Google Scholar
• Rao, B. B., B. H. Click, I. E. Koutroubakis, C. Ramos Rivers, M. Regueiro, J. Swoger, M. Schwartz, J. Hashash, A. Barrie, M. A. Dunn, et al. 2017. The cost of Crohn's disease: Varied health care expenditure patterns across distinct disease trajectories. Inflammatory Bowel Diseases 23(1): 107–15. doi:10.1097/MIB.0000000000000977
   PubMed Web of Science ®Google Scholar
• Samaan, M., S. Campbell, G. Cunningham, A. G. Tamilarasan, P. M. Irving, and S. McCartney. 2019. Biologic therapies for Crohn's disease: Optimising the old and maximising the new. F1000Research 8: F1000 Faculty Rev-1210. doi:10.12688/f1000research.18902.1
   Google Scholar
• Schwark Pratt, W., Z. Zhao, B. Mitchell, K. Ashpole, and K. J. Gregor. 2019. Diabetes payer-addressable burden: An actuarial analysis. North American Actuarial Journal 23(3): 386–94. doi:10.1080/10920277.2019.1566077
   Web of Science ®Google Scholar
• Wilson, M., A. Lucas, A. Cameron, and M. Luo. 2018. Budget impact of adding vedolizumab to a health plan formulary as another first-line biologic option for ulcerative colitis and Crohn's disease. American Health & Drug Benefits 11(5): 253–62.
   PubMed Web of Science ®Google Scholar
• Wolf, D. C., S. Jaganathan, C. Burudpakdee, A. Seetasith, R. Low, E. Lee, J. Gucky, M. Yassine, and D. A. Schwartz. 2018. Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: Results from a retrospective analysis of patient claims and home health nurse data. Patient Preference and Adherence 12: 869–78. doi:10.2147/PPA.S148777
   PubMed Web of Science ®Google Scholar
• Ye, Y., S. Manne, W. R. Treem, and D. Bennett. 2020. Prevalence of inflammatory bowel disease in pediatric and adult populations: Recent estimates from large national databases in the United States, 2007–2016. Inflammatory Bowel Diseases 26(4): 619–25.
   PubMed Web of Science ®Google Scholar